

**ATTACHMENT I**

# McKenna & Cuneo, LLP

Attorneys at Law

Los Angeles

San Francisco

San Diego

1900 K Street, N.W. ■ Washington, D.C. 20006-1108

202-496-7500 ■ Fax: 202-496-7756

www.mckennacuneo.com

Denver

Dallas

Brussels

October 21, 1999

Larry R. Pilot

202-496-7561

[larry\\_pilot@mckennacuneo.com](mailto:larry_pilot@mckennacuneo.com)

Dockets Management Branch  
Food and Drug Administration  
Department of Health and Human Services  
Room 23  
12420 Parklawn Drive  
Rockville, Maryland 20857

Re: Petition For Reconsideration  
Docket No. 99P-1516

Dear Sir or Madam:

The undersigned submits this petition for reconsideration of the decision of the Commissioner of Food and Drugs in Docket No. 99P-1516.

## A. Decision Involved

The Food and Drug Administration (FDA) through an October 6, 1999 letter from the Director of the Center for Devices and Radiological Health (CDRH) decided to deny the above referenced petition. Irrespective of the fact that this decision was expressed by the CDRH Director rather than the Commissioner as described in 21 C.F.R. § 10.30, it is the "wish" of the petitioner that the Commissioner of the Food and Drug Administration (FDA) reconsider the apparent decision of the FDA.

## B. Action Requested

The petitioner requests that the Commissioner undertake to identify "Reprocessed Single Use Devices" as Banned Devices in accordance with Section 516 of the Federal Food, Drug, and Cosmetic Act (FDCA), 21 U.S.C. 360f and the "Banned Devices" regulation appearing in the Code of Federal Regulations (C.F.R.) at 21 C.F.R. Part 895. The objective of this petition was to seek the prompt banning

99P-1516

PRC 1

Dockets Management Branch

October 21, 1999

Page 2

of reprocessed single use devices, but it invoked on page 8 of the petition the regulations appearing in 21 C.F.R. Part 895 recognizing that ultimate banning of these reprocessed single use devices would necessitate application of the procedures appearing in this regulation.

The petitioner recognizes the flexibility that the Commissioner possesses under 21 C.F.R. § 10.30(e) to "grant or deny such a petition, in whole or in part, and . . . grant such other relief or take other action as the petition warrants" as well as to provide a tentative response. The petitioner believes action by the Commissioner, other than denial, represent available and appropriate options for the FDA to assure that adulterated and/or misbranded devices do not remain in interstate commerce.

### C. Statement of grounds

The factual and legal grounds upon which the petition relies are described in the petition itself. Moreover, the applicable FDA regulation states that "A petition for reconsideration may not be based on information and views not contained in the administrative record on which the decision was made." 21 C.F.R. § 10.33(e). The petitioner recognizes that administrative records may exist which are not in the public file for Docket No. 99-1516. Therefore, it cannot address issues which may be part of the administrative record; because, such administrative record documents in the possession of the FDA have not been disclosed.

The petitioner can and does comment on the two-page document conveyed by the FDA as grounds for denial. Both the denial letter and the petitioner's response appear as Exhibit A. Quite simply, the MDMA believes that the October 6, 1999 letter makes quite clear that relevant information or views were neither previously nor adequately considered.

In reference to the documents appearing in Exhibit A, it should be obvious to any reader that the brief two paragraph "reasoning" for denial bears no resemblance to the substance of the twenty (20) pages of the petition. As a matter of fact, the one paragraph cites a "clear evidence" standard or justification for denial though such a threshold is not mandated either under the FDCA or the Banned Devices regulation. The petition itself provides a clear description of the FDCA criteria, the legislative references providing meaning to these criteria; and references, including documented evidence (e.g., see p. 15 of petition referencing FDA Docket No. 97N-0477), in support of the criteria identified in the FDCA.

Dockets Management Branch

October 21, 1999

Page 3

The petitioner recognizes that promulgation of a regulation requires notice and comment rulemaking. It also recognizes that the FDA can undertake to gather evidence, including consultation with a statutory advisory panel, prior to proceeding with publication of a proposed regulation. Publication of a proposal will provide the public with the opportunity to comment and may result in the production of evidence to demonstrate harm and/or the level of public deception. The possibility that the FDA may not make a proposed regulation immediately effective was not intended by the petitioner as a reason to abandon the process of identifying reprocessed single use devices as banned devices. It was for this reason, in part, that the petition on page 8 referenced the application of the Banned Device Regulations appearing in 21 C.F.R. Part 895. The petitioner believed then and restates now that the criteria for application of 21 C.F.R Part 895 are present and have been expressed in the petition.

The four sentence paragraph relied on by the FDA in the October 6, 1999 letter to support its reasoning improperly relies on a non-existent "clear evidence" criterion. Moreover, the failure of the FDA to provide an analysis of its review of the petition, and the absence of any explanation or identification of the "adverse event reports" are a pathetic effort to ignore the substance of the petition and represent arbitrary, capricious, and abuse of discretionary authority conduct by the FDA.

With regard to the five sentence paragraph in the October 6, 1999 letter referencing the concept of deception, the FDA attributes a suggestion to the petition for which there simply is no basis in fact or the text of the petition. The petition addresses the criteria applicable to the concept of substantial deception. It properly cites the legislative reference that no "...actual proof of deception of or injury to an individual [is] required." As a matter of fact, the previously cited Banned Devices regulation discusses criteria for determining whether a device is deceptive. In part, the regulation at 21 C.F.R. § 895.21(a)(2) states:

The Commissioner is not required to determine that there was an intent on the part of the manufacturer, distributor, importer, or any other responsible person (s) to mislead or otherwise harm users of the device or that there exists any actual proof of deception of, or injury to, an individual. (Emphasis Added).

Yet, the FDA, in defiance of its own regulation, which has been in effect for twenty years, denies the petition on the basis that there is "no evidence" of danger to

Dockets Management Branch

October 21, 1999

Page 4

health. Irrespective of whether "evidence" is a synonym for "proof", the fact in law is that "actual proof" of "deception" is "not required" to initiate a banning procedure.

The justification by the FDA, as distinct from its improper characterization of the petition, represents a careless effort to deny a carefully worded and substantive petition relying on both fact and law. The public is entitled to better performance by the FDA. The petitioner believes that it has met the burden to justify initiation of a proceeding to identify reprocessed single use devices as banned devices. It reiterates this plea to the Commissioner herself in this petition for reconsideration.

The petitioner believes that if the Commissioner will display careful consideration and a thorough analysis of this petition that she will identify an option other than the inadequate missive conveyed on October 6, 1999. Moreover, conscientious review by the Commissioner will confirm that:

- 1) The petition demonstrates that relevant information or views contained in the administrative record were not previously or not adequately considered.
- 2) The petitioner's position is not frivolous and is being pursued in good faith.
- 3) The petitioner has demonstrated sound public policy grounds supporting reconsideration.
- 4) Reconsideration is not outweighed by public health or other public interest - to the contrary, public health and public interest justify the need for the FDA to prevent unequivocal adulteration and misbranding of single use devices rather than act after the death or serious injury has occurred.

As part of this request to the Commissioner for reconsideration, the petitioner further requests that the Commissioner direct the recusal of individuals in the CDRH or elsewhere in the FDA who were involved in any way with the October 6, 1999 letter unless such involvement is open to the public and all records of such prior involvement are disclosed through filings in the docket for 99P-1516.


**McKenna & Cuneo, L.L.P.**

Attorneys at Law

Dockets Management Branch  
October 21, 1999  
Page 5

In summary, the MDMA appreciates this opportunity for reconsideration and welcomes the possibility of any reasonable initiative by the Commissioner to address an issue of major importance to the public health responsibility of the FDA.

(Signature)



(Name of Petitioner)

by Larry R. Pilot, Esq.  
McKenna & Cuneo, L.L.P.  
Counsel to Petitioner  
Medical Devices Manufacturers  
Association  
1900 K Street, N.W.  
Washington, D.C. 20006  
(202) 496-7561

LRP/gmf